All sponsors

Genentech, Inc. $RO.SW

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO56%

Delay Index: of 9 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.4 months). See all sponsors →

Open Genentech, Inc. on the live radar map → 📅 $RO.SW readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Giredestrant
NCT05306340
P3Active, not recruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer3732025-07-16 (+11 mo)
BRAVE
NCT06524375
P2Active, not recruitingChronic Lymphocytic Leukemia1182026-10-28 (-3 mo)
NAUTIKA1
NCT04302025
P2Active, not recruitingNon-small Cell Lung Cancer992026-11-30 (-14 mo)
Docetaxel
NCT00781612
P2Active, not recruitingNeoplasm Metastasis3782027-06-30
Kirros
NCT06096779
P2Active, not recruitingHepatocellular Carcinoma302027-07-30 (+15 mo)
MorningSun
NCT05207670
P2Active, not recruitingNon-Hodgkin Lymphoma3202027-07-31 (+7 mo)
RO7837195
NCT06979336
P2RecruitingUlcerative Colitis2242027-08-25
GDC-1261
NCT07567846
P1/2RecruitingAdvanced Prostate Cancer; Metastatic Prostate Cancer2602027-11-30
RIVULET
NCT07448038
P2RecruitingAtherosclerosis1622028-01-31
MoonROSE
NCT07100106
P1/2RecruitingBreast Cancer2852028-08-31 (-23 mo)
RO7965032
NCT07851259
P2RecruitingGeographic Atrophy Secondary to Age-Related Macular Degeneration3212030-08-21
IMCODE003
NCT05968326
P2Active, not recruitingAdenocarcinoma, Pancreatic Ductal2602031-01-01 (+19 mo)
OpRegen
NCT05626114
P2RecruitingGeographic Atrophy602031-03-01 (+17 mo)
Giredestrant
NCT07541079
P3RecruitingEarly Breast Cancer3002032-06-30